[Epidemiological trial of the prophylactic effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases]
- PMID: 3898670
[Epidemiological trial of the prophylactic effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases]
Abstract
The epidemiological effectiveness of dipyridamol, an interferon-inducing agent used for the prevention of influenza and viral acute respiratory diseases, was tested in 4 epidemiological trials, 3 of them carried out as double blind trials. Observations were made in groups of adults (a research institute, a factory) and children (a kindergarten, a school), comprising 1040 subjects in the test groups and 771 subjects in the control groups. The drug was used during the whole epidemic period (January--March 1983) according to the following schedule: 1 oral administration in 8 days, in doses of 8 mg for adults, 50 mg for schoolchildren and 24 mg for children in the kindergarten. The epidemiological effectiveness of the drug was evaluated by comparing the total morbidity rates in influenza and acute respiratory diseases in the test and control groups. The results of 4 trials showed a pronounced epidemiological effectiveness of dipyridamol. The values of the epidemiological effectiveness index of the drug were 2.38 in the kindergarten, 1.55 at the school, 7.42 at the factory and 2.16 at the research institute. The results of the study of dipyridamol suggest that further investigations should be made with a view to use it for the mass prevention of influenza and acute respiratory diseases.
Similar articles
-
[Evaluation of dipyridamole efficacy as an agent for preventing acute respiratory viral diseases].Vopr Virusol. 1987 May-Jun;32(3):294-7. Vopr Virusol. 1987. PMID: 3314143 Clinical Trial. Russian.
-
[Prophylaxis of respiratory infections outbreaks with dipyridamol in young servicemen].Voen Med Zh. 2004 Feb;325(2):39-43, 96. Voen Med Zh. 2004. PMID: 15101293 Clinical Trial. Russian.
-
[Improvement of natural resistance in children for prophylaxis of influenza and acute respiratory tract viral infections (results of multicenter randomized trials)].Antibiot Khimioter. 2009;54(9-10):37-41. Antibiot Khimioter. 2009. PMID: 20415263 Clinical Trial. Russian.
-
[THE USE OF CYCLOFERON FOR THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY VIRAL INFECTIONS].Klin Med (Mosk). 2015;93(3):57-63. Klin Med (Mosk). 2015. PMID: 26168605 Review. Russian.
-
[Kagocel in the therapy of influenza and acute respiratory viral infections: Data analysis and systematization from the results of preclinical and clinical trials].Ter Arkh. 2017;89(8):113-119. doi: 10.17116/terarkh2017898113-119. Ter Arkh. 2017. PMID: 28914861 Review. Russian.
Cited by
-
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.Acta Pharm Sin B. 2020 Jul;10(7):1205-1215. doi: 10.1016/j.apsb.2020.04.008. Epub 2020 Apr 20. Acta Pharm Sin B. 2020. PMID: 32318327 Free PMC article.
-
[Treatment for viral respiratory infections: Principles of action, strategies, and future prospects].Internist (Berl). 2004 Apr;45(4):468-75. doi: 10.1007/s00108-003-1111-5. Internist (Berl). 2004. PMID: 15021931 Free PMC article. Review. German.
-
Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.Viruses. 2016 Sep 29;8(10):269. doi: 10.3390/v8100269. Viruses. 2016. PMID: 27690086 Free PMC article. Review.
-
No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.JMIRx Med. 2020 Sep 30;1(1):e19583. doi: 10.2196/19583. eCollection 2020 Jan-Dec. JMIRx Med. 2020. PMID: 33724265 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical